OBJECTIVE: To investigate clinical efficacy of Xueshuantong injection combined with urokinase on the formation of deep venous thrombosis. METHODS: 56 cases of deep venous thrombosis were divided into control group and treatment group, 28 cases in the control group conventional urokinase thrombolysis, low molecular weight heparin anticoagulation, aspirin, anliplate-let adhesion, low molecular weight dextran expansion. Treatment group on the basis of the control group plus treated with Xueshuantong injection. RESULTS: After treatment, the patency rates between the 2 groups have no significant differences (P>0.05); Blood viscosity in the 2 groups of patients after thrombolysis compared with before thrombolysis significantly decline, in the treatment group with lower blood viscosity, compared with the control group were significantly different (P0.05); When follow-up, the high incidence of lower extremity varicose veins, lower extremity deep venous valve insufficiency was higher in control group (P0.05). CONCLUSION: Application Xueshuantong on the basis of the urokinase joint treatment of deep vein thrombosis, can play a good synergy, and the forward effect is better than the traditional western medicine therapy.%目的:观察血栓通注射液联合尿激酶对下肢深静脉血栓形成的临床疗效.方法:56例下肢深静脉血栓形成患者均分为2组,对照组常规采用尿激酶溶栓,低分子肝素钙抗凝,阿司匹林祛聚,低分子右旋糖酐扩容；治疗组在对照组基础上加用血栓通注射液治疗.治疗后观察、比较2组疗效及相关指标.结果:2组患者溶栓后下肢静脉通畅率比较无显著性差异(p＞0.05)；2组患者溶栓后血液黏度较溶栓前显著下降,同时治疗组患者血液黏度下降更低,与对照组比较差异有统计学意义(P＜0.05)；治疗组皮下出血、内脏出血、皮肤过敏、发热反应发生率均略高于对照组,但2组间比较,差异无统计学意义(＞0.05)；对照组于随访期内下肢浅静脉曲张、下肢深静脉瓣膜功能不全发生率高于治疗组(P＜0.05);对照组足靴区皮肤色素沉着、下肢行走时疼痛发生率也高于治疗组,但2组比较差异无统计学意义(P＞0.05).结论:血栓通注射液联合尿激酶治疗下肢深静脉血栓形成,可发挥较好的协同作用,远期效果好.
展开▼
